SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors are a class of drugs originally developed for type 2 diabetes that show promise for neurodegenerative disease modification through multiple mechanisms including reduced neuroinflammation, enhanced autophagy, and improved cerebral glucose metabolism.
- FDA-approved safety profile: SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) have established safety in millions of patients with diabetes
- Cross-disease mechanisms: Multiple mechanistic links between metabolic dysfunction and neurodegeneration provide therapeutic rationale
- Clinical evidence emerging: Retrospective analyses show reduced dementia risk in SGLT2 inhibitor users
- BBB penetration: Some SGLT2 inhibitors cross the blood-brain barrier at therapeutic doses
flowchart TD
subgraph Primary_Mechanisms
A["SGLT2 Inhibition"] --> B["Reduced Blood Glucose"]
A --> C["Ketone Body Elevation"]
B --> D["Reduced Glycation Stress"]
B --> E["Improved Insulin Sensitivity"]
C --> F["Enhanced Brain Energy Metabolism"]
end
subgraph Neuroprotective_Effects
F --> G["Enhanced Autophagy"]
F --> H["Reduced Oxidative Stress"]
E --> I["Improved Mitochondrial Function"]
D --> J["Reduced AGEs Formation"]
end
subgraph Disease_Modification
G --> K["Reduced Protein Aggregation"]
H --> L["Neuronal Protection"]
I --> M["Enhanced Cellular Resilience"]
J --> N["Improved Synaptic Function"]
end
| Disease |
Patient Selection |
Rationale |
| Alzheimer's Disease |
MCI or early AD with metabolic syndrome |
Strongest rationale - addresses insulin resistance |
| Parkinson's Disease |
Early PD with diabetes risk factors |
May improve mitochondrial function |
| ALS |
Bulbar or limb onset, early stage |
Limited evidence but mechanistic plausibility |
- Population: Early AD (MCI-AD or mild AD), ages 55-85
- Intervention: Empagliflozin 10mg daily vs placebo for 52 weeks
- Primary endpoints:
- Change in cerebral glucose metabolism (FDG-PET)
- Change in CSF biomarkers (Aβ42, p-tau, total-tau)
- Secondary endpoints:
- Cognitive function (ADAS-Cog13, MMSE)
- Brain volume (MRI)
- Motor function (UPDRS in PD subset)
| Biomarker |
Expected Change |
Measurement |
| FDG-PET |
Increased cerebral glucose metabolism |
Baseline, week 26, week 52 |
| CSF Aβ42 |
Increased (improved clearance) |
Baseline, week 52 |
| CSF p-tau |
Reduced or stable |
Baseline, week 52 |
| NfL |
Reduced trajectory |
Baseline, week 12, 26, 52 |
- GLP-1 Receptor Agonists + SGLT2i for enhanced metabolic restoration
- Complementary mechanisms: GLP-1 enhances insulin signaling, SGLT2i reduces glucose
- Autophagy-Proteostasis Dual Activation + SGLT2i
- Synergistic enhancement of protein clearance
¶ Competitive Landscape
| Drug |
Company |
BBB Penetration |
Clinical Stage |
| Empagliflozin (Jardiance) |
Boehringer-Ingelheim |
Moderate |
Planned |
| Dapagliflozin (Farxiga) |
AstraZeneca |
Low |
Preclinical |
| Canagliflozin (Invokana) |
Janssen |
Very Low |
Preclinical |
¶ Challenges and Considerations
- Off-target effects: Renal function must be monitored; contraindicated in severe renal impairment
- Dosing: May need higher doses than diabetes indications for CNS effects
- Mechanism clarity: Exact CNS mechanisms still being elucidated
- Competition: Multiple companies may pursue similar strategies
- GLP-1 Receptor Agonist Therapy
- Metabolic-Energetic Restoration
- Metformin Neuroprotection (planned)